Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview

Panchal, Kanan; Sahoo, Rakesh Kumar; Gupta, Umesh; Chaurasiya, Akash

doi:10.1016/j.intimp.2021.107508

Cited by 24 publications

(14 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The existing therapeutic options have failed to provide an appropriate response in PDAC, reinforcing the unlucky privilege of being one of the deadliest cancers worldwide ( Latenstein et al, 2020 ). Regrettably, even immunotherapy, which has recently revolutionized the drug regimes in cancer treatment ( Makaremi et al, 2021 ), has shown few successful chances in PDAC due to tumor-related stroma abundance ( Panchal et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines

et al. 2022

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all pancreatic cancers. Albeit its incidence does not score among the highest in cancer, PDAC prognosis is tremendously fatal. As a result of either aggressiveness or metastatic stage at diagnosis, chemotherapy constitutes the only marginally effective therapeutic approach. As gemcitabine (Gem) is still the cornerstone for PDAC management, the low response rate and the onset of resistant mechanisms claim for additional therapeutic strategies. The first synthetic orally active adiponectin receptor agonist AdipoRon (AdipoR) has recently been proposed as an anticancer agent in several tumors, including PDAC. To further address the AdipoR therapeutic potential, herein we investigated its pharmacodynamic interaction with Gem in human PDAC cell lines. Surprisingly, their simultaneous administration revealed a more effective action in contrasting PDAC cell growth and limiting clonogenic potential than single ones. Moreover, the combination AdipoR plus Gem persisted in being effective even in Gem-resistant MIA PaCa-2 cells. While a different ability in braking cell cycle progression between AdipoR and Gem supported their cooperating features in PDAC, mechanistically, PD98059-mediated p44/42 MAPK ablation hindered combination effectiveness. Taken together, our findings propose AdipoR as a suitable partner in Gem-based therapy and recognize the p44/42 MAPK pathway as potentially involved in combination outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Traditional chemotherapeutics have poor accuracy on tumor cells and are prone to adverse reactions. Therefore, the targeted therapy is particularly important for tumor therapy (45)(46)(47). Peptides specifically binding to tumor tissues, as carriers to direct drugs to tumor tissues, significantly improved the accuracy of drug targeting (48)(49)(50)(51).…”

Section: Biopanning the Tumor-targeted Peptidementioning

confidence: 99%

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

et al. 2021

View full text Add to dashboard Cite

Glioma is a life-threatening malignant tumor. Resistance to traditional treatments and tumor recurrence present major challenges in treating and managing this disease, consequently, new therapeutic strategies must be developed. Crossing the blood-brain barrier (BBB) is another challenge for most drug vectors and therapy medications. Filamentous bacteriophage can enter the brain across the BBB. Compared to traditional drug vectors, phage-based drugs offer thermodynamic stability, biocompatibility, homogeneity, high carrying capacity, self-assembly, scalability, and low toxicity. Tumor-targeting peptides from phage library and phages displaying targeting peptides are ideal drug delivery agents. This review summarized recent studies on phage-based glioma therapy and shed light on the developing therapeutics phage in the personalized treatment of glioma.

show abstract

“…Immunotherapeutic agents target the immunity mediators and empower them to suppress the tumor and effectively treat PDAC. Different targets are studied and exploited to induce an antitumor immune response in PDAC patients ( 5 ). The PDAC microenvironment consists of cancer cells, stromal cells, and extracellular components.…”

Section: Introductionmentioning

confidence: 99%

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma

Zhang

Huang

2022

Front. Oncol.

View full text Add to dashboard Cite

Pancreatic cancer has the seventh highest death rate of all cancers. The absence of any serious symptoms, coupled with a lack of early prognostic and diagnostic markers, makes the disease untreatable in most cases. This leads to a delay in diagnosis and the disease progresses so there is no cure. Only about 20% of cases are diagnosed early. Surgical removal is the preferred treatment for cancer, but chemotherapy is standard for advanced cancer, although patients can eventually develop drug resistance and serious side effects. Chemoresistance is multifactorial because of the interaction among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment (TME). Nevertheless, more pancreatic cancer patients will benefit from precision treatment and targeted drugs. This review focuses on the immune-related components of TME and the interactions between tumor cells and TME during the development and progression of pancreatic cancer, including immunosuppression, tumor dormancy and escape. Finally, we discussed a variety of immune components-oriented immunotargeting drugs in TME from a clinical perspective.

show abstract

Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview

Cited by 24 publications

References 165 publications

Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines

Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About